Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena
Renato V. Iozzo, James D. San Antonio
Renato V. Iozzo, James D. San Antonio
Published August 1, 2001
Citation Information: J Clin Invest. 2001;108(3):349-355. https://doi.org/10.1172/JCI13738.
View: Text | PDF
Perspective

Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena

  • Text
  • PDF
Abstract

Authors

Renato V. Iozzo, James D. San Antonio

×

Figure 2

Options: View larger image (or click on image) Download as PowerPoint
The yin (perlecan) and yang (type XVIII collagen) of angiogenic regulati...
The yin (perlecan) and yang (type XVIII collagen) of angiogenic regulation by heparan sulfate proteoglycans (top panel). Perlecan, syndecans, and glypicans are proposed to act as coreceptors to deliver proangiogenic factors to their high-affinity cell surface receptors. As shown for perlecan, angiogenic stimulation might follow from its increased expression or cell surface accessibility. This would result in release of growth factors such as VEGF, carried by specific heparan sulfate sequences, or FGF2 and FGF7, bound to either heparan sulfate chains or unique regions of the protein core (middle panel). These events promote the cell proliferation phase of angiogenesis and may also trigger the synthesis and release of a battery of proteinases into the ECM milieu. Proteinases in turn would degrade perlecan, thus attenuating its growth-promoting activities, and liberate endostatin from type XVIII collagen (bottom panel). Endostatin is proposed to block VEGF- and FGF-mediated angiogenic signaling, thereby maintaining the endothelium in a quiescent state.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts